Vor Biopharma Inc
NASDAQ:VOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vor Biopharma Inc
Other Liabilities
Vor Biopharma Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vor Biopharma Inc
NASDAQ:VOR
|
Other Liabilities
$603.3m
|
CAGR 3-Years
157%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$2.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
Vor Biopharma Inc
Glance View
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. The company is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. The company offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.
See Also
What is Vor Biopharma Inc's Other Liabilities?
Other Liabilities
603.3m
USD
Based on the financial report for Dec 31, 2025, Vor Biopharma Inc's Other Liabilities amounts to 603.3m USD.
What is Vor Biopharma Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
103%
Over the last year, the Other Liabilities growth was 2 085%. The average annual Other Liabilities growth rates for Vor Biopharma Inc have been 157% over the past three years , 103% over the past five years .
